Mode
Text Size
Log in / Sign up
N/A N=129 Randomized Basic Science

Metabolic Impact of Intermittent CPAP

Obstructive Sleep Apnea

Enrolled (actual)
129
Serious AEs
0.0%
Results posted
Jan 2024
Primary outcome: Primary: Concentration of Plasma Free Fatty Acids (FFA, mmol/L) — 0.47; 0.51 mmol/L

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
CPAP withdrawal (Other)
Age
Adult, Older Adult · 20+ yrs
Sex
All
Sponsor
Johns Hopkins University
Primary completion
Dec 2022

Outcome Measures

OutcomeResultp-value
PRIMARY
Concentration of Plasma Free Fatty Acids (FFA, mmol/L)
0.47; 0.51
PRIMARY
Concentration of Plasma Glucose (mg/dl)
100; 101
PRIMARY
Concentration of Plasma Insulin (mcU/ml)
18; 18
PRIMARY
Concentration of Plasma Triglycerides (mg/dl)
127; 128
SECONDARY
Oral Glucose Tolerance Test (OGTT)
19820; 19224
SECONDARY
Reactive Hyperemia Index (RHI)
2.21; 2.12
SECONDARY
Augmentation Index (AI)
3.3; 6.3

Summary

Obstructive sleep apnea is a risk factor for diabetes and cardiovascular disease, by unknown mechanisms. The investigators hypothesize that sleep apnea changes glucose and lipid metabolism during sleep, which over time could lead to diabetes and cardiovascular disease. This study examines metabolic changes during sleep in patients with obstructive sleep apnea. Patients accustomed to continuous positive airway pressure (CPAP) therapy are enrolled to undergo sleep studies, either on CPAP therapy or after withdrawing from CPAP for 3 nights. During sleep, blood samples are obtained so that metabolic function can be compared between sleep apnea and CPAP nights.

Eligibility Criteria

Inclusion Criteria

  • History of moderate to severe Obstructive sleep apnea (OSA) (AHI or respiratory disturbance index (RDI)> 10).
  • They must also own a CPAP machine and report the ability to tolerate sleeping with or without CPAP during the night.

Exclusion Criteria

  • Uncontrolled hypertension with systolic blood pressure >170 or diastolic blood pressure > 110
  • Congestive heart failure
  • Use of clonidine or nicotinic acid medication
  • Diabetes requiring the use of insulin
  • Known pregnancy, by urine testing in women of child-bearing age
  • History of falling asleep while driving, near miss
  • High risk occupation (pilot, commercial driver)
  • Hemoglobin < 10 g/dL on point of care screening
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02824263). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search